Moderna Vaccines-Day-2022(4)莫德纳疫苗报告.pdf

DNA mRNA Protein Third Annual Vaccines Day Thursday, March 24th, 2022 Forward-looking statements and Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the impact of vaccination on global health, economies and social welfare; the return on healthcare investment in vaccines; the potential for the Company’s mRNA platform to disrupt the traditional vaccines market; the Company’s ability to produce combination vaccines and bring many vaccines to market; the Company’s ability to expand its portfolio and address critical unmet medical needs with its mRNA platform; the Company’s plans to expand its portfolio of global public health vaccines to 15 total programs, and the timing for advancing these vaccine programs; the timing for a transition into the ende mic phase of the COVID-19 pandemic; the expected seasonal impact on future sales of vaccines; the Company’s development of vaccines against COVID-19, including efforts to develop variant-specific and multivalent vaccines against variant strains of SARS-CoV-2 and for booster doses; use of the Company’s COVID-19 vaccine in adolescents and pediatrics, the status of testing and approvals for these populations and the potential for mRNA-1273 to provide protection from COVID-19 in vaccine recipients down to 6 months of age; the Company’s plans to move forward with regulatory submissions for authorization of mRNA-1273 for primary vaccination of infants and children both in and outside of the U.S.; the safety and tolerability of mRNA-1273 in pediatric populations; the Company’s plans to evaluate a booster dose for all pediatric populations and adolescents; the potency and effectiveness of mRNA-1283 and timing for commencement of a Phase 3 study; the ability of mRNA-1283 to facilitate distribution and administration by h